Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Blood

• Publication date

  2008-04-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/blood-2007-10-116475PMID 18256322
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity.

  2007cited by this paper
• How I treat chronic myeloid leukemia in the imatinib era.

  2007cited by this paper
• Imatinib Disposition and ABCB1 (MDR1, P‐Glycoprotein) Genotype

  2007cited by this paper
• Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia.

  2007influential reference
• Chronic myeloid leukemia in 2006 : a perspective

  2006cited by this paper
• Long-term follow-up of a phase II randomized trial in advanced gastrointestinal stromal tumor (GIST) patients (pts) treated with imatinib mesylate.

  2006cited by this paper
• Compliance and persistency with imatinib.

  2006cited by this paper
• Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate

  2006cited by this paper
• Intensive surveillance after stage II or III colorectal cancer: is it worth it?

  2006cited by this paper
• Discontinuation of imatinib therapy after achievement of complete molecular response in a Ph(+) CML patient treated while in long lasting complete cytogenetic remission (CCR) induced by interferon.

  2006cited by this paper
• Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.

  2006cited by this paper
• Prescription compliance and persistency in chronic myelogenous leukemia (CML) and gastrointestinal stromal tumor (GIST) patients (pts) on imatinib (IM).

  2006cited by this paper
• Molecular remission in chronic myeloid leukemia patients with sustained complete cytogenetic remission after imatinib mesylate treatment.

  2006influential reference
• Clinical Pharmacokinetics of Imatinib

  2005cited by this paper
• Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study.

  2005cited by this paper
• Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme.

  2005cited by this paper
• hOCT 1 and resistance to imatinib.

  2005cited by this paper
• Active transport of imatinib into and out of cells: implications for drug resistance.

  2004cited by this paper
• Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects

  2004cited by this paper
• Discontinuation of imatinib therapy after achieving a molecular response.

  2004cited by this paper
• NCCN Task Force report: optimal management of patients with gastrointestinal stromal tumor (GIST)--expansion and update of NCCN clinical practice guidelines.

  2004cited by this paper
• Effect of St John's Wort on imatinib mesylate pharmacokinetics

  2004cited by this paper
• The Influence of St. John's Wort on the Pharmacokinetics and Protein Binding of Imatinib Mesylate

  2004cited by this paper
• Imatinib therapy for chronic myeloid leukemia

  2004cited by this paper
• Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients.

  2004influential reference
• Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects

  2004cited by this paper
• Genetics of the variable expression of CYP3A in humans.

  2004cited by this paper
• P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate

  2004cited by this paper
• Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

  2003influential reference
• Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.

  2003cited by this paper
• Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.

  2003cited by this paper
• Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors.

  2002cited by this paper
• High-throughput quantification of the anti-leukemia drug STI571 (Gleevec) and its main metabolite (CGP 74588) in human plasma using liquid chromatography-tandem mass spectrometry.

  2002cited by this paper
• Cytochrome P4503A (CYP3A) metabolism: Prediction ofIn Vivo activity in humans

  1996cited by this paper

• Nitrogen blowing DµSPE of sunitinib, imatinib, and dasatinib using LDH/MIL-101(Cr)-NO2 composite prior to HPLC-PDA.

  2026cites this paper
• Novel phenylamino pyrimidine derivatives as potent and selective inhibitors of ABL1 tyrosine kinase for targeted anticancer therapy.

  2026cites this paper
• Macrocytosis as an Early Pharmacodynamic Marker of Imatinib Efficacy in Chronic Myeloid Leukemia

  2026cites this paper
• Unveiling the impact of adherence: imatinib plasma levels and survival in postoperative gastrointestinal stromal tumor (GIST) patients

  2025cites this paper
• Precision Medicine in Oncology: Imatinib Dosing in the Obese Cancer Population Using Virtual Clinical Trials

  2025cites this paper
• Therapeutic drug monitoring of imatinib in paediatric chronic myeloid leukaemia: Data from a real‐world setting

  2025cites this paper
• A deep dive into the surgical and pharmacological considerations of obesity in chronic myeloid leukemia: a narrative review

  2025cites this paper
• Therapeutic Drug Monitoring: A Driver to Precision Medicine for Patients with Hematological Malignancies

  2025cites this paper
• Charge-sensitive detection of imatinib with monolayer WS2-based plasmonic sensor

  2025cites this paper
• Distinct endothelial cell toxicities of Abl tyrosine kinase inhibitors lead to arterial thrombosis

  2025cites this paper
• Improving quality of life for patients with chronic myeloid leukemia through supportive care, low-dose therapy, switching, and treatment-free remission.

  2025cites this paper
• Dispersive solid phase extraction of imatinib from human plasma using biological metal-organic and covalent-organic framework composite prior to HPLC-MS/MS.

  2025cites this paper
• Exposure-response analysis of oral and intravenous imatinib in critically ill patients with COVID-19 Acute Respiratory Distress Syndrome.

  2025cites this paper
• Assessing endothelial cytotoxicity induced by tyrosine kinase inhibitors: insights from Raman and fluorescence imaging.

  2025cites this paper
• Published Population Pharmacokinetic Models of Imatinib Perform Poorly on TDM Data from Pediatric Patients

  2025cites this paper
• Estimating cure and risk of death from other causes of adolescent and young adult cancer patients in Europe.

  2025cites this paper
• Ponatinib, But Not the New Abl-Kinase Inhibitor Asciminib, Activates Platelets, Leukocytes, and Endothelial Cell TNF Signaling to Induce Atherosclerotic Plaque Inflammation, Myocardial Infarction, and Stroke.

  2025cites this paper
• Genetic and Non-genetic Correlates of Imatinib Pharmacokinetics and Side Effects of Imatinib in Palestinian Patients with Chronic Myeloid Leukemia.

  2025cites this paper
• From Prospective Evaluation to Practice: Model-Informed Dose Optimization in Oncology

  2025cites this paper
• Body mass index affects imatinib exposure: Real‐world evidence from TDM with adaptive dosing

  2025cites this paper
• Advanced gastrointestinal stromal tumor: reliable classification of imatinib plasma trough concentration via machine learning

  2024cites this paper
• Engineering of CuMOF-SWCNTs@AuNPs-Based Electrochemical Sensors for Ultrasensitive and Selective Monitoring of Imatinib in Human Serum

  2024cites this paper
• Rethinking Dosimetry: The Perils of Extrapolated External-Beam Radiotherapy Constraints to Radionuclide Therapy

  2024cites this paper
• A novel fluorescent probe based imprinted polymer-coated magnetite for the detection of imatinib leukemia anti-cancer drug traces in human plasma samples.

  2024cites this paper
• Constitutional DNA Polymorphisms Associated with the Plasma Imatinib Concentration in Chronic Myeloid Leukemia Patients

  2024cites this paper
• Association between plasma imatinib levels and response to treatment of chronic myeloid leukemia in patients from Manaus, Brazil

  2024cites this paper
• Clinical pharmacokinetics and Drug-drug interactions of tyrosine-kinase inhibitors in chronic myeloid leukemia: a clinical perspective.

  2024cites this paper
• Influence of CYP2C8*3 and ABCG2 C421A genetic polymorphisms on trough concentration and molecular response of imatinib in Egyptian patients with chronic myeloid leukemia

  2024cites this paper
• Промежуточные результаты российского проспективного многоцентрового клинического исследования READIT-2020 (снижение дозы ингибиторов тирозинкиназ при ХМЛ, концентрация иматиниба/нилотиниба в плазме, сохранение молекулярного ответа, лекарственная токсичность)

  2024cites this paper
• Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.

  2024cites this paper
• Therapeutic options for chronic myeloid leukemia following the failure of second-generation tyrosine kinase inhibitor therapy

  2024cites this paper
• Long-term Outcomes of tyrosine kinase inhibitors in chronic myeloid leukemia.

  2024cites this paper
• Pharmacogenomics and Personalized Medicine

  2024cites this paper
• Biopharmaceutical and pharmacokinetic attributes to drive nanoformulations of small molecule tyrosine kinase inhibitors

  2024cites this paper
• A case-matched study of imatinib mesylate between different formulations on plasma trough concentration, adverse events, quality of life and outcomes in gastrointestinal stromal tumor patients

  2024cites this paper
• Tyrosine Kinase Inhibitors in Cancers: Treatment optimization - Part II.

  2024cites this paper
• Simultaneous determination of three tyrosine kinase inhibitors and three triazoles in human plasma by LC-MS/MS: applications to therapeutic drug monitoring and drug-drug interaction studies.

  2024cites this paper
• Therapeutic drug monitoring of imatinib – how far are we in the leukemia setting?

  2024cites this paper
• Therapeutic Drug Monitoring of Imatinib: Is There a Rationale for Also Quantifying Its Active Metabolite?

  2024cites this paper
• Imatinib pharmacokinetics and creatine kinase levels in chronic myeloid leukemia patients: implications for therapeutic response and monitoring

  2024cites this paper
• Pharmacokinetics of single- and multiple-dose flumatinib in patients with chronic phase chronic myeloid leukemia

  2023cites this paper
• Hematological Adverse Events with Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: A Systematic Review with Meta-Analysis

  2023cites this paper
• Differential vascular endothelial cell toxicity of established and novel BCR-ABL tyrosine kinase inhibitors

  2023cites this paper
• Pharmacokinetics of Imatinib Mesylate and Development of Limited Sampling Strategies for Estimating the Area under the Concentration–Time Curve of Imatinib Mesylate in Palestinian Patients with Chronic Myeloid Leukemia

  2023influential citation
• Population pharmacokinetics and pharmacogenetics analyses of imatinib in Chinese patients with chronic myeloid leukemia in a real-world situation

  2023cites this paper
• Association of Microrna-153-3p Expression in Response to Treatment with Imatinib in Patients with Chronic Myeloid Leukemia

  2023cites this paper
• Pharmacokinetics of Four Tyrosine Kinase Inhibitors in Adult and Paediatric Chronic Myeloid Leukaemia Patients

  2023cites this paper
• Bullous Pemphigoid Occurring after Stopping Imatinib Therapy of CML: Is a Continuation of Post-Treatment Follow-Up Needed?

  2023cites this paper
• Are novel oral oncolytics underdosed in obese patients?

  2023cites this paper
• Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology

  2023cites this paper
• Framework for Implementing Individualised Dosing of Anti-Cancer Drugs in Routine Care: Overcoming the Logistical Challenges

  2023cites this paper
• Application of physiologically based pharmacokinetic modeling to understand real‐world outcomes in patients receiving imatinib for chronic myeloid leukemia

  2023cites this paper
• CO-RELATION OF P-GLYCOPROTEIN AND PLASMA IMATINIB IN IMATINIB RESPONDERS AND NON-RESPONDERS PATIENTS WITH CHRONIC MYELOID LEUKAEMIA

  2023cites this paper
• Population modeling of bosutinib exposure‐response in patients with newly diagnosed chronic phase chronic myeloid leukemia

  2023cites this paper
• Risk Factors for Palbociclib-Induced Early Developing Neutropenia in Patients with Hormone Receptor-Positive Metastatic Breast Cancer

  2023cites this paper
• From Personalized to Precision Medicine in Oncology: A Model-Based Dosing Approach to Optimize Achievement of Imatinib Target Exposure

  2023influential citation
• The importance of personalized medicine in chronic myeloid leukemia management: a narrative review

  2023cites this paper
• A customized mass array panel for BCR::ABL1 tyrosine kinase domain mutation screening in chronic myeloid leukemia

  2023cites this paper
• Changes in imatinib plasma trough level during long-term treatment in patients with intermediate- or high-risk gastrointestinal stromal tumors: Relationship between covariates and imatinib plasma trough level

  2023cites this paper
• Pharmacokinetics and pharmacodynamics of imatinib for optimal drug repurposing from cancer to COVID-19

  2023cites this paper
• Association between bariatric surgery and outcomes in chronic myeloid leukemia

  2023cites this paper
• Electrochemical determination of imatinib mesylate using TbFeO3/g-C3N4 nanocomposite modified glassy carbon electrode

  2023cites this paper
• Fabrication, characterization and performance evaluation of an amplified electrochemical sensor based on MOFs nanocomposite for leukemia drug Imatinib determination

  2023cites this paper
• Zebrafish Cancer Avatars: A Translational Platform for Analyzing Tumor Heterogeneity and Predicting Patient Outcomes

  2023cites this paper
• Plasma trough concentration of imatinib and its effect on therapeutic efficacy and adverse events in Japanese patients with GIST

  2023cites this paper
• Therapy Resistance and Disease Progression in CML: Mechanistic Links and Therapeutic Strategies

  2022cites this paper
• The application of virtual therapeutic drug monitoring to assess the pharmacokinetics of imatinib in a Chinese Cancer population group.

  2022cites this paper
• Volumetric dried blood microsampling for monitoring imatinib mesylate therapy: Method development and clinical application in patients with chronic myeloid leukemia.

  2022cites this paper
• Impact of Genetic Polymorphisms and Biomarkers on the Effectiveness and Toxicity of Treatment of Chronic Myeloid Leukemia and Acute Myeloid Leukemia

  2022cites this paper
• Imatinib plasma levels in patients with gastrointestinal stromal tumour under routine clinical practice conditions

  2022cites this paper
• CYP2D6 and CYP2C8 pharmacogenetics and pharmacological interactions to predict imatinib plasmatic exposure in GIST patients

  2022cites this paper
• Novel pyrazolo[3,4-d]pyrimidines as dual Src/Bcr-Abl kinase inhibitors: Synthesis and biological evaluation for chronic myeloid leukemia treatment.

  2022cites this paper
• Imatinib Optimized Therapy Improves Major Molecular Response Rates in Patients with Chronic Myeloid Leukemia

  2022cites this paper
• Imatinib dose optimization based on therapeutic drug monitoring in Chinese patients with chronic‐phase chronic myeloid leukemia

  2022cites this paper
• Role of ADME gene polymorphisms on imatinib disposition: results from a population pharmacokinetic study in chronic myeloid leukaemia

  2022cites this paper
• Enhanced oral bioavailability and antitumor therapeutic efficacy of sorafenib administered in core–shell protein nanoparticle

  2022cites this paper
• Real-world data on the efficacy and safety of adjuvant chemotherapy in Japanese patients with a high-risk of gastrointestinal stromal tumor recurrence

  2022cites this paper
• Development, validation, and application of an UPLC-MS/MS method for vancomycin, norvancomycin, methotrexate, paclitaxel, and imatinib analysis in human plasma

  2022cites this paper
• Outcomes of adolescents and young adults with chronic-phase chronic myeloid leukaemia treated with tyrosine kinase inhibitors

  2022cites this paper
• Real‐world efficacy and safety outcomes of imatinib treatment in patients with chronic myeloid leukemia: An Australian experience

  2022cites this paper
• Relevance of Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors in Routine Clinical Practice: A Pilot Study

  2022cites this paper
• Elevated acute phase proteins affect pharmacokinetics in COVID‐19 trials: Lessons from the CounterCOVID ‐ imatinib study

  2021cites this paper
• Therapeutic drug monitoring in oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology consensus guidelines for imatinib therapy.

  2021cites this paper
• Imatinib plasma levels in patients with chronic myeloid leukaemia under routine clinical practice conditions

  2021influential citation
• Precision Dosing of Targeted Therapies Is Ready for Prime Time

  2021cites this paper
• Physiologically‐based pharmacokinetic model predictions of inter‐ethnic differences in imatinib pharmacokinetics and dosing regimens

  2021cites this paper
• Therapeutic drug monitoring for the cancer patient: challenges and opportunities

  2021cites this paper
• Therapeutic Drug Monitoring of Imatinib in Patients of Chronic Myeloid Leukemia - Chronic Phase

  2021influential citation
• Imatinib: The First-Line CML Therapy

  2021cites this paper
• External evaluation of population pharmacokinetic models of imatinib in adults diagnosed with chronic myeloid leukaemia

  2021cites this paper
• Evaluating the utility of therapeutic drug monitoring in the clinical use of small molecule kinase inhibitors: a review of the literature

  2021influential citation
• Induction of autophagy has protective roles in imatinib-induced cardiotoxicity

  2021cites this paper
• Changes of Drug Pharmacokinetics in Patients with Short Bowel Syndrome: A Systematic Review

  2021cites this paper
• Optimized preconcentration of Imatinib using dispersive liquid-liquid microextraction coupled with HPLC-UV

  2021cites this paper
• The Oncogenic Protein, Breakpoint Cluster (BCR)-Abelson Kinase (ABL) and Chronic Myelocytic Leukemia (CML): Insight Into the Drug Resistance Mechanisms and Approaches for Targeting BCR-ABL in CML

  2021cites this paper
• Opportunities of Chronic Myeloid Leukemia Treatment with Reduced Doses of Tyrosine Kinase Inhibitors

  2021cites this paper
• Intracerebral hemorrhage as a rare complication of imatinib in a Philadelphia chromosome positive acute lymphoblastic leukemia pediatric patient

  2021cites this paper
• Impact of socio-demographic co-variates on prognosis, tyrosine kinase-inhibitor use and outcomes in persons with newly-diagnosed chronic myeloid leukaemia

  2021cites this paper
• Individualized Management of Blood Concentration in Patients with Gastrointestinal Stromal Tumors

  2021cites this paper
• Method development for determination of imatinib and its' major metabolite, N-desmethyl imatinib, in biological and environmental samples by SA-SHS-LPME and HPLC.

  2021cites this paper